Evidence map›Paper›PMID 42644871›Full record

SynthesisAdvances in respiratory medicine2026

Nanocarrier-Based Drug Delivery Systems for Lung Cancer: A Systematic Review and Meta-Analysis of Preclinical Studies.

Pranvera Breznica Selmani, Arlinda Daka Grapci, Blerina Koshi, Zana Sllamniku Dalipi, Rozafa Koliqi

Abstract readSystematic ReviewMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Advances in respiratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pranvera Breznica SelmaniDepartment of Pharmaceutical Chemistry, Pharmacy Division, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.ORCID 0000-0001-9928-2543
Arlinda Daka GrapciDepartment of Clinical Pharmacy and Biopharmacy, Pharmacy Division, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.
Blerina KoshiDepartment of Pharmaceutical Technology, Pharmacy Division, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.
Zana Sllamniku DalipiDepartment of Dentistry, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.ORCID 0000-0003-3957-969X
Rozafa KoliqiDepartment of Clinical Pharmacy and Biopharmacy, Pharmacy Division, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.ORCID 0000-0001-7160-3755

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug delivery systems (DDS) may improve the therapeutic performance of chemotherapy in lung cancer, but their preclinical efficacy has not been quantitatively synthesized. We conducted a systematic review and meta-analysis of controlled in vivo mouse studies evaluating DDS-based chemotherapeutic formulations for lung cancer. Databases were searched from inception to 15 February 2025, and methodological quality was assessed using the SYRCLE risk-of-bias tool. Thirty studies comprising 47 experiments were included. Compared with corresponding free-drug treatments, DDS-based chemotherapy significantly reduced tumor volume (WMD -310.67 mm

Indexed as

Antineoplastic AgentsDrug CarriersDrug Delivery SystemsLung NeoplasmsNanoparticlesAnimalsHumansMiceAntineoplastic AgentsDrug Carrierschemotherapycombination therapydrug delivery systemslung cancermeta-analysisnanoparticlespreclinical modelstargeted therapytumor inhibition

Identifiers

PMID42644871
PMCPMC13509827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.